Literature DB >> 9702657

Current results and evolving indications for liver transplantation in children.

D A Kelly1.   

Abstract

Liver transplantation continues to be successful and effective treatment for acute and chronic liver failure, and many important lessons have been learned. The development of innovative operative techniques has much reduced the waiting list mortality rate and has extended transplantation to younger and sicker children and to those with functionally normal livers who may benefit from auxiliary liver transplantation. The incidence and range of postoperative complications have improved with increased medical and surgical expertise. As information on long-term outcome for liver transplantation is gained, it is clear that many children will benefit from early elective liver transplantation before the development of significant growth or psychosocial retardation. Early transplantation is also indicated in children with cirrhosis and intrapulmonary shunting or cystic fibrosis with moderate lung disease. During the same period, evolving medical therapy has altered the natural history, patient selection, and timing of transplantation in children with tyrosinaemia type I, primary bile acid disorders, neonatal haemochromatosis, and potentially, cystic fibrosis. It is now clear that children with significant multisystem disease, such as mitochondrial disorders or severe systemic oxalosis, are no longer suitable candidates for liver transplantation. The successful development of liver transplantation has brought good quality life to many children and their families. There are still many lessons to learn and there are future challenges such as the ever-increasing problems of donor scarcity and the search for potent but less toxic immunosuppressive agents.

Entities:  

Mesh:

Year:  1998        PMID: 9702657     DOI: 10.1097/00005176-199808000-00017

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  9 in total

1.  Paediatric transplantation comes of age. The main problem now is shortage of donors.

Authors:  D Kelly; A Mayer
Journal:  BMJ       Date:  1998-10-03

Review 2.  Immunosuppressive drugs in paediatric liver transplantation.

Authors:  I D van Mourik; D A Kelly
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

3.  Progress in treatment and outcome for children with neonatal haemochromatosis.

Authors:  D M Flynn; N Mohan; P McKiernan; S Beath; J Buckels; D Mayer; D A Kelly
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-03       Impact factor: 5.747

Review 4.  New management options for end-stage chronic liver disease and acute liver failure: potential for pediatric patients.

Authors:  Dominique Debray; Nadya Yousef; Philippe Durand
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 5.  Therapy for acute rejection in pediatric organ transplant recipients.

Authors:  Dominique Debray; Válerie Furlan; Véronique Baudouin; Lucile Houyel; Florence Lacaille; Christophe Chardot
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

6.  Current status of liver transplantation.

Authors:  Deirdre Kelly; Anupam Sibal
Journal:  Indian J Pediatr       Date:  2003-09       Impact factor: 1.967

Review 7.  Strategies for optimizing immunosuppression in adolescent transplant recipients: a focus on liver transplantation.

Authors:  Deirdre A Kelly
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.930

8.  Liver transplantation in Greek children: 15 years experience.

Authors:  Ioannis Xinias; Antigoni Mavroudi; Olga Vrani; Georgios Imvrios; Dimitrios Takoudas; Kleomenis Spiroglou
Journal:  Pediatr Rep       Date:  2010-09-06

9.  Pamidronate decreases bilirubin-impaired cell death and improves dentinogenic dysfunction of stem cells from human deciduous teeth.

Authors:  Haruyoshi Yamaza; Soichiro Sonoda; Kazuaki Nonaka; Toshio Kukita; Takayoshi Yamaza
Journal:  Stem Cell Res Ther       Date:  2018-11-08       Impact factor: 6.832

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.